Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Enhanced CAR-T activity against established tumors by polarizing human T cells to secrete interleukin-9.

Nature communications - 19 Nov 2020

Liu Lintao, Bi Enguang, Ma Xingzhe, Xiong Wei, Qian Jianfei, Ye Lingqun, Su Pan, Wang Qiang, Xiao Liuling, Yang Maojie, Lu Yong, Yi Qing

Abstract excerpt

CAR-T cell therapy is effective for hematologic malignancies. However, considerable numbers of patients relapse after the treatment, partially due to poor expansion and limited persistence of CAR-T cells in vivo. Here, we demonstrate that human CAR-T cells polarized and expanded under a Th9-culture condition (T9 CAR-T) have an enhanced antitumor activity against established tumors. Compared to IL2-polarized (T1)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytotoxicity, Immunologic
Share to Immunologic Memory

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunotherapy, Adoptive

Share to Interferon-gamma

Share to Precursor Cell Lymphoblastic Leukemia-Lymphoma

Share to Receptors, Chimeric Antigen

Share to Th1 Cells

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 33214555
DOI: 10.1038/s41467-020-19672-2
PMCID: PMC7677397

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Enhanced CAR-T activity against established tumors by polarizing human T cells to secrete interleukin-9.PMID 33214555Read ↗

Focusing on CD8+ T-cell phenotypes: improving solid tumor therapy.Semantic proximity Read ↗

PiggyBac Transposon-Mediated CD19 Chimeric Antigen Receptor-T Cells Derived From CD45RA-Positive Peripheral Blood Mononuclear Cells Possess Potent and Sustained Antileukemic Function.Semantic proximity Read ↗

CAR‐T‐cell products in solid tumors: Progress, challenges, and strategiesSemantic proximity Read ↗

Ex vivo culture of chimeric antigen receptor T cells generates functional CD8+ T cells with effector and central memory-like phenotype.Semantic proximity Read ↗

Resident Memory T Cells and Their Effect on CancerSemantic proximity Read ↗

ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cellsSemantic proximity Read ↗

CD29 marks superior cytotoxic human T cellsSemantic proximity Read ↗

Breaking the immunosuppressive barrier: an armored CAR-M biotechnology with the original M1 phenotype dominance rescues antitumor immunity.Semantic proximity Read ↗

Single-Cell Analysis of CAR-T Cell Activation Reveals A Mixed T H 1/T H 2 Response Independent of DifferentiationSemantic proximity Read ↗

Identification and selective expansion of functionally superior T cells expressing chimeric antigen receptors.Semantic proximity Read ↗

Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapy.Semantic proximity Read ↗

Galectin-9 activates and expands human T-helper 1 cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.